Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: Results of a multivariate analysis on 273 patients

被引:28
作者
Benasso, M
Bonelli, L
Numico, G
Corvo, R
Sanguineti, C
Rosso, R
Vitale, V
Merlano, M
机构
[1] IST NAZL RIC CANC, DEPT BIOSTAT, I-16132 GENOA, ITALY
[2] IST NAZL RIC CANC, DEPT RADIAT ONCOL, I-16132 GENOA, ITALY
关键词
chemo-radiotherapy; head and neck cancer; prognostic factors;
D O I
10.1023/A:1008244110004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The goal of the present analyses is to assess the association between different therapeutic approaches and both the probability of achieving a complete response and the risk of death in patients with stage III-IV, inoperable, squamous cell carcinoma of the head and neck (SCC-HN). Patients and methods. Between August 1983 and December 1990, 273 patients with stage III-IV, previously untreated, unresectable SCC of the oral cavity, pharynx and larynx. were included into two consecutive randomized multi-institutional trials (HN-7 and HN-8 protocols) coordinated by the National Institute for Cancer Research (NICR) of Genoa. The HN-7 protocol compared neo-adjuvant chemotherapy (four cycles of vinblastine, 6 mg/m(2) i.v. followed by bleomycin, 30 IU i.m. six hours later, day 1; methotrexate, 200 mg i.v, day 2; leucovorin, 45 mg orally, day 3) (VBM) followed by standard radiotherapy (70-75 Gy in 7-8 weeks) (55 patients) to alternating chemoradiotherapy based on four cycles of the same chemotherapy alternated with three splits of radiation, 20 Gy each (61 patients). In the HN-8 protocol standard radiotherapy (77 patients) was compared to the same alternating program as the one used in the previous protocol but employing cisplatin, 20 mg/m(2)/day and fluorouracil, 200 mg/m(2)/day, bolus, both given for five consecutive days (CF) instead of VBM (80 patients). A single database was created with the patients oil the two protocols. Age at diagnosis, gender, site of the primary tumor, size of the primary, nodal involvement, performance status and treatment approach were analyzed by the multiple logistic regression model and the Cox regression method. The analyses were repeated including the treating institutions as a covariate (coordinating center versus others). Results: The multiple logistic regression analysis indicates that treatment (alternating more so than others, regardless of the chemotherapy regimen used) (P = 0.0001) is more likely to be associated with complete response. In addition, size of the primary tumor (P = 0.004), nodal involvement (P = 0.02) and performance status (P = 0.009) are prognostic variables affecting the probability of achieving a complete response. The Cox regression analysis indicates that treatment, performance status, size of the primary tumor, nodal involvement and, marginally, site of the primary tumor, are independent prognostic variables affecting the risk of death. When the radiation-alone therapy is adopted as the reference treatment, the relative risk of death is 0.58 (95% confidence interval (CI) 0.40-0.84) for alternating CF and radiation, 0.79 (95% CI 0.53-1.16) for alternating VBM and radiation and 1.30 (95% CI 0.89-1.92) for sequential VBM and radiation. When the treating institution is included in the model, a 34% increased risk of death (P = 0.004) is observed for patients treated outside the coordi nating center. Conclusion. In our series of patients with advanced, unresectable SCC-HN, treatment with cisplatin and fluorouracil alternating with radiation was associated with a more favourable prognosis. The role of the treating institution in the modulation of the treatment outcomes was also relevant.
引用
收藏
页码:773 / 779
页数:7
相关论文
共 22 条
  • [1] CEREZO L, 1992, CANCER, V69, P1224
  • [2] PROGNOSTIC FACTORS FOR CHEMOTHERAPY RESPONSE AND SURVIVAL USING COMBINATION CHEMOTHERAPY AS INITIAL TREATMENT OF ADVANCED HEAD AND NECK SQUAMOUS-CELL CANCER
    COGNETTI, F
    PINNARO, P
    RUGGERI, EM
    CARLINI, P
    PERRINO, A
    IMPIOMBATO, FA
    CALABRESI, F
    CHILELLI, MG
    GIANNARELLI, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) : 829 - 837
  • [3] DIXON WJ, 1993, BMDP STATISTICAL SOF
  • [4] Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials
    ElSayed, S
    Nelson, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 838 - 847
  • [5] COMBINED RADIOTHERAPY AND CHEMOTHERAPY WITH BLEOMYCIN AND METHOTREXATE FOR ADVANCED INOPERABLE HEAD AND NECK-CANCER - UPDATE OF A NORTHERN CALIFORNIA ONCOLOGY GROUP RANDOMIZED TRIAL
    FU, KK
    PHILLIPS, TL
    SILVERBERG, IJ
    JACOBS, C
    GOFFINET, DR
    CHUN, C
    FRIEDMAN, MA
    KOHLER, M
    MCWHIRTER, K
    CARTER, SK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1410 - 1418
  • [6] Survival outcome of care by specialist surgeons in breast cancer: A study of 3786 patients in the west of Scotland
    Gillis, CR
    Hole, DJ
    [J]. BRITISH MEDICAL JOURNAL, 1996, 312 (7024) : 145 - 148
  • [7] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [8] A RANDOMIZED STUDY OF ADJUVANT CHEMOTHERAPY FOR CANCER OF THE UPPER AERODIGESTIVE TRACT
    KUN, LE
    TOOHILL, RJ
    HOLOYE, PY
    DUNCAVAGE, JA
    BYHARDT, RW
    RITCH, PS
    GROSSMAN, TW
    HOFFMANN, RG
    COX, JD
    MALIN, T
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1986, 12 (02): : 173 - 178
  • [9] LOONEY WB, 1985, CANCER TREAT REP, V69, P769
  • [10] MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163